Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1073 (Moderna Inc)
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
mRNA-1073 is a combination mRNA vaccine developed by Moderna that targets both SARS-CoV-2 and seasonal influenza. It is a co-formulation of Moderna's quadrivalent influenza vaccine candidate (mRNA-1010) and its COVID-19 vaccine (mRNA-1273). The vaccine utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding the spike protein of SARS-CoV-2 and the hemagglutinin (HA) proteins of four seasonal influenza strains (A/H1N1, A/H3N2, B/Yamagata, and B/Victoria). It is designed to provide simultaneous protection against both respiratory viruses in a single injection, potentially improving vaccination compliance and public health efficiency.
- Other names
- COVID-19 and Influenza VaccineCOVID19 and Influenza VaccineCOVID 19 and Influenza VaccineSARS-CoV-2 and Influenza VaccineSARS-CoV2 and Influenza VaccineSARS-CoV 2 and Influenza Vaccine
02
Targets
HA (Hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA-1073 (Moderna Inc).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1073 (Moderna Inc).